How to Buy Y Mabs Therapeutics Stock
Y Mabs Therapeutics Inc
Y-mAbs Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.
Y Mabs Therapeutics stock last closed at $14.84, down 2.94% from the previous day, and has increased 156.75% in one year. It has overperformed other stocks in the Biotechnology industry by 1.8 percentage points. Y Mabs Therapeutics stock is currently +222.61% from its 52-week low of $4.60, and -29% from its 52-week high of $20.90.
At the moment, there are 43.78M YMAB shares outstanding. The market capitalization of YMAB is $649.65M. In the past 24 hours, 365,385 YMAB shares were traded.
How to Buy Y Mabs Therapeutics Stock
Not sure how to invest in Y Mabs Therapeutics stock? Here's how.
- Figure out where to buy Y Mabs Therapeutics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you determine where to buy Y Mabs Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Select your payment method and add your information.
- Research Y Mabs Therapeutics stock: The Y Mabs Therapeutics ticker symbol is YMAB. Is Y Mabs Therapeutics stock a good investment? Should you buy shares of YMAB? How do YMAB's underlying business fundamentals look? Do top analysts think Y Mabs Therapeutics is a good buy? Why has YMAB's stock price moved recently? (Hint: Our stock market analysis tools can help you figure out if YMAB is a good stock to buy).
- Make your YMAB buy order: Decide if you will purchase YMAB shares at the current market price or use a limit order to purchase YMAB stock at a particular price.
- Get updates on your YMAB investment: Create a watchlist to track your new investment in Y Mabs Therapeutics shares.
Step 1: Figure out where to buy Y Mabs Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy YMAB stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Real Estate, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen your brokerage, it's time to fill out some personal information so you are able to invest in YMAB stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to start your new trading account.
- Send your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've finished signing up on the stock trading app, you can securely and quickly fund your account:
Watch the walkthrough below if you need help depositing funds into your new investment account.
Step 4: Research Y Mabs Therapeutics stock
Once you have decided on the best place to buy Y Mabs Therapeutics stock, it's critical to evaluate their stock prior to investing, so you actually understand the risk and upside.
Y Mabs Therapeutics Metrics
Y Mabs Therapeutics Overview
WallStreetZen was designed to help everyday investors perform more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on YMAB's stock page.
What is the fair value of YMAB stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge YMAB's fair value.
Using relative valuations metrics:
- YMAB may be overvalued based on its P/B ratio of 6.43x, relative to Biotechnology industry P/B ratio of 5.8x
You can do more valuation analysis on YMAB's stock here.
YMAB Financial Health Overview
Pros:
- There are more short-term assets than short-term liabilities on the YMAB balance sheet.
- There are more short-term assets than long-term liabilities on the YMAB balance sheet.
- YMAB has $78.64M in cash and short term investments. This is enough to cover its annual cash burn of $27.23M.
- YMAB has cash burn of 27232000. It has enough cash and short-term investments to cover this for at least one year.
- YMAB has a low debt to equity ratio of 0.27.
Cons:
- Total YMAB debt is higher than 5 years ago, relative to shareholder equity.
- YMAB profit margin has gone up by 1.21 percentage points in the past year, but the company is still unprofitable.
Do Wall Street analysts think it's a good time to buy Y Mabs Therapeutics stock
Out of 3 Equities analysts who give forecasts on YMAB, the consensus analyst rating on YMAB is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are forecasting on the Y Mabs Therapeutics stock forecast page.
YMAB Momentum
Is YMAB Making Money?
Last year, YMAB revenue was $84.82M. In the past 3 year, YMAB's revenue has gone up by 145.62% per year. This was faster than the Biotechnology industry average of 28.62%.
You can analyze YMAB's earnings and revenue performance here.
What are YMAB executives and large shareholders up to?
Over the last 12 months, insiders at YMAB have bought more shares than they have sold.
Thomas Gad, CHIEF BUSINESS OFFICER of YMAB, was the latest YMAB insider to sell. They sold $64,116.00 worth of YMAB shares on Mar 5, 2024.
Research more about who owns YMAB shares here.
Does YMAB stock generate passive income?
No, Y Mabs Therapeutics doesn't provide an income stream by paying out dividends.
YMAB Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your YMAB buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually the easiest way to buy. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact dollar amount limit, use a limit order.
Hit the Open Trade button and your broker will execute your order.
If you want more help investing in stocks on eToro, watch the helpful video below:
Step 6: Get updates on your YMAB investment
Now that you own some YMAB shares, you'll want to keep up with your new investment.
Create a watchlist to get notified of the latest news about your YMAB stock.
YMAB Feed
How to Buy Stock in Y Mabs Therapeutics
To summarize, here are the 6 steps to buy stock in Y Mabs Therapeutics:
- Figure out where to buy Y Mabs Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Research Y Mabs Therapeutics stock
- Make your YMAB buy order
- Get updates on your YMAB investment
If you need a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep an eye on your new investment in Y Mabs Therapeutics, add YMAB to your watchlist by clicking the button below.
Other "How To" Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.